Recurrent Cervical Carcinoma Clinical Trials

43 clinical trials for Recurrent Cervical Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer — RECRUITING · PHASE2
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers — RECRUITING · PHASE1
• Paclitaxel Therapeutic Drug Monitoring in Cancer Patients — SUSPENDED
• Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Dostarlimab and Cobolimab in Advanced Cervical Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer — ACTIVE_NOT_RECRUITING
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer — TERMINATED · PHASE1
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis — COMPLETED · PHASE1
• DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers — TERMINATED · PHASE2
• Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers — TERMINATED · PHASE1
• Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers — COMPLETED · PHASE1
• MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer — TERMINATED
• SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer — COMPLETED · PHASE2
• Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer — COMPLETED · PHASE2
• Tislelizumab and Radiotherapy for Recurrent Cervical Cancer — OTHER · PHASE2
• PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer — OTHER
• Donafenib for Recurrent Cervical Cancer — OTHER · PHASE2
• Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial — OTHER · PHASE2
• First-line Chemotherapy for Recurrent Cervical Cancer — COMPLETED · PHASE2
• Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy — COMPLETED · PHASE2
• Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma — OTHER · PHASE2
• Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas — OTHER · PHASE2
• Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies — COMPLETED · NA
• Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer — COMPLETED · PHASE3
• Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer — COMPLETED · PHASE1
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations — COMPLETED · PHASE1
• Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix — COMPLETED · PHASE3
• the Re-irradiation of Recurrent Cervical Cancer by IMRT — OTHER · NA
• Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer — COMPLETED
• Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2
• Collecting Tumor Samples From Patients With Gynecological Tumors — COMPLETED
• Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer — COMPLETED · PHASE2
• Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery — COMPLETED · PHASE2
• Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer — COMPLETED · PHASE2
• Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer — COMPLETED · PHASE2

Refine this search